|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B
Anna S. Lok
Fabien Zoulim
Geoffrey Dusheiko
Henry L.Y. Chan
Maria Buti
Marc G. Ghany
Anuj Gaggar
Jenny C. Yang
George Wu
John F. Flaherty
G. Mani Subramanian
… See all authors
First published: 10 October 2019
https://doi.org/10.1002/hep4.1436
Citations: 1
Supported by Gilead Sciences.
Potential conflict of interest: Dr. Locarnini consults for Gilead, Clear‐B, and I‐Hep/Janssen. Dr. Dusheiko consults for and received grants from Gilead. Dr. Buti consults for and advises Gilead. Dr. Subramanian, Dr. Yang, Dr. Wu, Dr. Flaherty, and Dr. Gaggar own stock in and are employed by Gilead. Dr. Chan consults for and is on the speakers’ bureau for Gilead and Roche. Dr. Marcellin consults for and received grants from Gilead, Merck, and Eiger; he consults for Hebaziz, is on the speakers’ bureau for Mylan, and received grants from AbbVie. Dr. Zoulim received grants from and consults for Roche; he consults for Janssen and Gilead and received grants from Evotec. Dr. Lok advises and received grants from Gilead and Target; she advises Huahui, Roche, SpringBank, and Viravaxx and received grants from Assembly and BMS. Dr. Ghany has nothing to report.
SEE EDITORIAL ON PAGE 5
Sections
ePDFPDF
Tools
Share
Abstract
In patients with chronic hepatitis B (CHB), loss of hepatitis B surface antigen (HBsAg) is considered a functional cure. However, HBsAg loss is uncommon with existing therapies, and predictive factors associated with HBsAg seroreversion are unknown. Using pooled data from three phase 3 clinical trials of patients with CHB treated with nucleos(t)ide analogue (NUC) monotherapy or peginterferon (Peg‐IFN) ± NUC combination therapy, we conducted a retrospective analysis to characterize patients who achieved sustained HBsAg loss, the predictors of HBsAg seroreversion, and the impact of hepatitis B surface antibody (anti‐HBs) seroconversion on durability of HBsAg loss. In these three international trials, 1,381 adults with CHB received either NUC monotherapy for up to 10 years or Peg‐IFN‐containing regimens for up to 1 year. A total of 55 patients had confirmed HBsAg loss, defined as two or more consecutive negative‐qualitative HBsAg results, with a minimum of one repeat result after the end of treatment. Throughout a median of 96 (quartile [Q]1, Q3, 46, 135) weeks follow‐up after HBsAg loss, HBsAg loss was durable in 82% (n = 45) of patients, with 10 patients experiencing HBsAg seroreversion. Anti‐HBs seroconversion was observed during follow‐up in 78% of patients who lost HBsAg and in 60% of those who subsequently seroreverted. In analyzing predictors of HBsAg seroreversion, study treatment was significant, yet anti‐HBs seroconversion and treatment duration after initial HBsAg loss were not. Risk of HBsAg seroreversion was observed to be lower if HBsAg loss was sustained through the off‐treatment week 24 visit (8/10 seroreversions occurred by posttreatment week 24). Conclusion: HBsAg loss after NUC or Peg‐IFN‐containing regimens was durable in 82% of patients with CHB. Anti‐HBs seroconversion and treatment duration after initial HBsAg loss were not significantly associated with durability of HBsAg loss.
Abbreviations
ALT
alanine aminotransferase
anti‐HBs
hepatitis B surface antibody
CHB
chronic hepatitis B
HBeAg
hepatitis B e antigen
HBsAg
hepatitis B surface antigen
HBV
hepatitis B virus
HCC
hepatocellular carcinoma
IU
international unit
KM
Kaplan‐Meier
LLOD
lower limit of detection
NUC
nucleos(t)ide
Peg‐IFN
peginterferon
Q
quartile
TDF
tenofovir disoproxil fumarate
|
|
发表于 2020-1-8 19:20
